Neurocrine Biosciences’ (NBIX) Hold Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a report published on Monday morning,Benzinga reports.

Several other research analysts also recently commented on the company. Jefferies Financial Group boosted their target price on Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a report on Monday, August 19th. Citigroup boosted their price objective on Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a “neutral” rating in a research note on Friday, August 2nd. StockNews.com lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Raymond James reiterated an “outperform” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Finally, Royal Bank of Canada lowered their price objective on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research report on Friday, October 4th. Five analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX opened at $122.88 on Monday. The business has a fifty day moving average of $118.53 and a two-hundred day moving average of $132.88. Neurocrine Biosciences has a 52-week low of $107.84 and a 52-week high of $157.98. The stock has a market cap of $12.44 billion, a PE ratio of 32.94 and a beta of 0.35.

Institutional Trading of Neurocrine Biosciences

Institutional investors have recently made changes to their positions in the business. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in Neurocrine Biosciences by 0.8% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 11,436 shares of the company’s stock worth $1,574,000 after buying an additional 90 shares in the last quarter. Fifth Third Bancorp raised its holdings in Neurocrine Biosciences by 14.7% during the second quarter. Fifth Third Bancorp now owns 716 shares of the company’s stock worth $99,000 after acquiring an additional 92 shares in the last quarter. Total Clarity Wealth Management Inc. boosted its position in Neurocrine Biosciences by 4.3% during the second quarter. Total Clarity Wealth Management Inc. now owns 2,433 shares of the company’s stock valued at $335,000 after purchasing an additional 100 shares during the last quarter. Commerce Bank grew its stake in Neurocrine Biosciences by 2.6% in the third quarter. Commerce Bank now owns 4,199 shares of the company’s stock valued at $484,000 after purchasing an additional 108 shares in the last quarter. Finally, Caprock Group LLC increased its position in shares of Neurocrine Biosciences by 7.0% during the 2nd quarter. Caprock Group LLC now owns 1,669 shares of the company’s stock worth $230,000 after purchasing an additional 109 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.